NCT03548818

Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 9 (actual)
• Sponsor: University of Colorado, Denver · Academic / Other
• Sex: All
• Age: 5 Years – 60 Years
• Healthy volunteers: —

Summary

The overall goal of the study is to investigate the functional, biochemical, and gene expression effects of Interferon-gamma 1-b (IFN-γ) on the neutrophils of patients with Chronic Granulomatous Disease (CGD). The investigators hypothesize that the clinical effects demonstrated in patients with CGD treated with IFN-γ (decreased number and severity of infections) are the result of biochemical processes and upregulation of specific genes, which lead to enhanced functionality of this immune cell population.

Conditions

• Chronic Granulomatous Disease

Interventions

Type	Name	Description
DRUG	Interferon Gamma-1B	Study function and biochemistry of neutrophils off the drug for one week and then 12 hours after first dose and fourth dose.

Timeline

• Start date: 2018-05-16
• Primary completion: 2020-07-15
• Completion: 2020-07-15
• First posted: 2018-06-07
• Last updated: 2021-01-22

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study